THE FOLLOW UP
STATEMENT

Executive Order signed to improve medical marijuana and cannabidiol research to better inform patients and doctors.

True

Evidence from credible sources supports the statement as accurate. Learn more in Methodology.

Interesting: 0/0 • Support: 0/0Log in to vote
directive

Executive Order signing completed and directives to improve research take effect.

Source summary
President Donald J. Trump signed an Executive Order directing federal actions to expand research and access around medical marijuana and hemp-derived cannabidiol (CBD). The Order instructs the Attorney General to expedite rescheduling marijuana to Schedule III, directs HHS to develop real-world evidence research methods, and asks the White House Deputy Chief of Staff to work with Congress on access to appropriate full-spectrum CBD products. The administration cites HHS and FDA findings, existing state medical programs, and usage statistics to argue the changes will improve guidance for patients and doctors.
View original article →
Latest fact check

On December 18, 2025, President Donald J. Trump signed an Executive Order aimed at enhancing medical marijuana and cannabidiol (CBD) research to better inform patients and doctors. The order directs the Attorney General to expedite the process of rescheduling marijuana to Schedule III of the Controlled Substances Act, which would recognize its medical use. Additionally, it instructs the Deputy Chief of Staff for Legislative, Political, and Public Affairs to collaborate with Congress to improve access to full-spectrum CBD products while regulating those that pose health risks. The Department of Health and Human Services (HHS) is also tasked with developing research methods utilizing real-world evidence to improve access to hemp-derived cannabinoid products and inform standards of care. (whitehouse.gov)

Sources

Timeline

  1. Update · Dec 21, 2025, 08:56 AMTrue
    On December 18, 2025, President Donald J. Trump signed an Executive Order aimed at enhancing medical marijuana and cannabidiol (CBD) research to better inform patients and doctors. The order directs the Attorney General to expedite the process of rescheduling marijuana to Schedule III of the Controlled Substances Act, which would recognize its medical use. Additionally, it instructs the Deputy Chief of Staff for Legislative, Political, and Public Affairs to collaborate with Congress to improve access to full-spectrum CBD products while regulating those that pose health risks. The Department of Health and Human Services (HHS) is also tasked with developing research methods utilizing real-world evidence to improve access to hemp-derived cannabinoid products and inform standards of care. (whitehouse.gov)
  2. Update · Dec 21, 2025, 07:45 AMTrue
    President Donald J. Trump signed an Executive Order on December 18, 2025, aimed at enhancing medical marijuana and cannabidiol (CBD) research to better inform patients and doctors. The Order directs the Attorney General to expedite the rescheduling of marijuana to Schedule III of the Controlled Substances Act, facilitates access to full-spectrum CBD products, and mandates the Department of Health and Human Services to develop research methods utilizing real-world evidence to improve access to hemp-derived cannabinoid products. (whitehouse.gov)
  3. Update · Dec 21, 2025, 07:00 AMTrue
    On December 18, 2025, President Donald J. Trump signed an Executive Order aimed at improving medical marijuana and cannabidiol (CBD) research to better inform patients and doctors. The order directs the Attorney General to expedite the process of rescheduling marijuana from a Schedule I to a Schedule III substance under the Controlled Substances Act, aligning with the Department of Health and Human Services' 2023 recommendation recognizing marijuana's medical use. Additionally, the order mandates the development of research methods utilizing real-world evidence to enhance access to hemp-derived cannabinoid products and inform standards of care. (whitehouse.gov)
  4. Update · Dec 21, 2025, 05:52 AMTrue
    On December 18, 2025, President Donald J. Trump signed an Executive Order aimed at improving medical marijuana and cannabidiol (CBD) research to better inform patients and doctors. The order directs the Attorney General to expedite the rescheduling of marijuana from a Schedule I to a Schedule III substance under the Controlled Substances Act, aligning with the Department of Health and Human Services' 2023 recommendation recognizing marijuana's medical use. Additionally, the order mandates the development of research methods utilizing real-world evidence to assess the health outcomes of medical marijuana and CBD products, focusing on long-term effects in vulnerable populations. (whitehouse.gov)
  5. Update · Dec 21, 2025, 05:04 AMTrue
    President Donald J. Trump signed an Executive Order on December 18, 2025, aimed at enhancing medical marijuana and cannabidiol (CBD) research to better inform patients and doctors. The Order directs the Attorney General to expedite the process of rescheduling marijuana to Schedule III of the Controlled Substances Act, which would recognize its medical use. Additionally, it mandates the Deputy Chief of Staff for Legislative, Political, and Public Affairs to collaborate with Congress to allow Americans access to appropriate full-spectrum CBD products while restricting those that pose health risks. The Department of Health and Human Services (HHS) is also tasked with developing research methods utilizing real-world evidence to improve access to hemp-derived cannabinoid products and inform standards of care. (whitehouse.gov)
  6. Update · Dec 21, 2025, 04:22 AMTrue
    President Donald J. Trump signed an Executive Order on December 18, 2025, aimed at enhancing medical marijuana and cannabidiol (CBD) research to better inform patients and doctors. The Order directs the Attorney General to expedite the rescheduling of marijuana to Schedule III of the Controlled Substances Act, facilitates access to full-spectrum CBD products, and mandates the Department of Health and Human Services to develop research methods utilizing real-world evidence. (whitehouse.gov)
  7. Update · Dec 21, 2025, 02:53 AMTrue
    On December 18, 2025, President Donald J. Trump signed an Executive Order aimed at improving medical marijuana and cannabidiol (CBD) research to better inform patients and doctors. The order directs the Attorney General to expedite the rescheduling of marijuana from Schedule I to Schedule III of the Controlled Substances Act, aligning with the Department of Health and Human Services' 2023 recommendation recognizing marijuana's medical use. Additionally, the order mandates the development of research methods utilizing real-world evidence to enhance access to hemp-derived cannabinoid products and inform standards of care. (whitehouse.gov)
  8. Update · Dec 20, 2025, 11:46 PMTrue
    President Donald J. Trump signed an Executive Order on December 18, 2025, aimed at enhancing medical marijuana and cannabidiol (CBD) research to better inform patients and doctors. The Order directs the Attorney General to expedite the rescheduling of marijuana to Schedule III of the Controlled Substances Act, facilitates access to full-spectrum CBD products, and mandates the Department of Health and Human Services to develop research methods utilizing real-world evidence. These actions are intended to improve the safety and efficacy of medical marijuana and CBD products. (whitehouse.gov)
  9. Update · Dec 20, 2025, 08:43 AMcomplete
    On December 18, 2025, President Donald J. Trump signed an Executive Order to improve medical marijuana and cannabidiol (CBD) research, aiming to better inform patients and doctors. The order directs the Attorney General to expedite rescheduling marijuana from Schedule I to Schedule III of the Controlled Substances Act, aligning with the Department of Health and Human Services' 2023 recommendation recognizing marijuana's medical use. Additionally, it mandates the development of research methods utilizing real-world evidence to enhance access to hemp-derived cannabinoid products and inform standards of care. (whitehouse.gov)
  10. Update · Dec 19, 2025, 07:33 AMcomplete
    On December 18, 2025, President Donald J. Trump signed an Executive Order to reclassify marijuana from a Schedule I to a Schedule III substance under the Controlled Substances Act. This reclassification aims to facilitate medical research by acknowledging marijuana's accepted medical use and reducing regulatory barriers. The order also directs the Attorney General to expedite this process and mandates the Department of Health and Human Services to develop research methods utilizing real-world evidence to improve access to hemp-derived cannabinoid products. (whitehouse.gov)
  11. Original article · Dec 18, 2025
    View article
Back to Countdowns

Comments

Only logged-in users can comment.
Loading…